American Journal of Translational Research,
Journal Year:
2024,
Volume and Issue:
16(10), P. 5990 - 6007
Published: Jan. 1, 2024
Ovarian
cancer
is
a
highly
lethal
gynecological
malignancy,
often
diagnosed
late,
resulting
in
high
mortality.
While
BRCA1
and
BRCA2
mutations
are
known
risk
factors,
the
broader
genetic
landscape
needs
comprehensive
profiling
to
identify
additional
diagnostic
markers
or
therapeutic
targets.
The
current
study
aims
explore
of
various
cancer-susceptible
genes
ovarian
patients.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(14), P. 9784 - 9797
Published: March 12, 2024
Extracellular
vesicles
(EVs)
secreted
by
all
cell
types
are
involved
in
the
cell-to-cell
transfer
of
regulatory
factors
that
influence
and
tissue
phenotypes
normal
diseased
tissues.
EVs
thus
a
rich
source
biomarker
targets
for
assays
analyze
blood
urinary
disease
diagnosis.
Sensitive
detection
derived
from
specific
populations
is
key
major
hurdle
when
analyzing
complex
biological
samples,
but
innovative
approaches
surveyed
this
Perspective
can
streamline
EV
isolation
enhance
sensitivity
procedures
required
clinical
application
EV-based
diagnostics
therapeutics,
including
nanotechnology
microfluidics,
to
achieve
characterizations.
Finally,
also
outlines
opportunities
challenges
remaining
translation
assays.
Cancer Letters,
Journal Year:
2023,
Volume and Issue:
580, P. 216481 - 216481
Published: Nov. 15, 2023
Small
extracellular
vesicles
(sEVs)
such
as
exosomes
are
nanoscale
membranous
particles
(<200
nm)
that
have
emerged
crucial
targets
for
liquid
biopsy
and
promising
drug
delivery
vehicles.
They
play
a
significant
role
in
tumor
progression
intercellular
messengers.
can
serve
biomarkers
diagnosis
carriers
cancer
treatment.
This
article
reviews
recent
studies
on
sEVs
oncology
explores
their
potential
Following
tumorigenesis,
the
microenvironment
(TME)
circulatory
system
undergo
modifications
to
regulate
various
events
TME,
including
angiogenesis,
epithelial-mesenchymal
transition
(EMT),
immunity,
with
either
pro-
or
anti-tumor
effects.
been
investigated
use
diagnostic
prognostic
variety
of
tumors,
lung
cancer,
melanoma,
breast
prostate
hepatocellular
carcinoma.
be
used
therapy
by
packaging
drugs
proteins
into
them
through
pre-
post-isolation
modification
techniques.
The
clinical
trials
also
summarized.
Finally,
challenges
described
possible
approaches
tackling
suggested.
Overall,
will
advance
precision
medicine
has
shown
great
applications.
ACS Sensors,
Journal Year:
2024,
Volume and Issue:
9(7), P. 3594 - 3603
Published: June 24, 2024
Extracellular
vesicles
(EVs)
are
preeminent
carriers
of
biomarkers
and
have
become
the
subject
intense
biomedical
research
for
medical
diagnostics
using
biosensors.
To
create
effective
EV-based
immunoassays,
it
is
imperative
to
develop
surface
chemistry
approaches
with
optimal
EV
detection
targeting
transmembrane
protein
that
not
affected
by
cell-to-cell
variability.
Here,
we
developed
a
series
immunoassays
EVs
derived
from
mouse
monocyte
cells
plasmon
resonance
(SPR)
We
chemically
immobilized
antibodies
onto
mixed
self-assembled
monolayers
oligo
ethylene
glycol
(OEG)
alkanethiolates
carboxylic
hydroxylic
terminal
groups.
The
effects
antibody
clonality
(monoclonal
vs
polyclonal)
coverage
in
via
CD81
tetraspanins
were
investigated.
determined
binding
kinetic
parameters,
establishing
trends
steric
hindrance
epitope
recognition
properties
antibodies.
Our
results
indicate
40%
polyclonal
covalently
linked
SAM
10%
terminated
−COOH
groups
yields
promising
approach
linear
range
1.9
×
108–1.9
109
EVs/mL
limit
5.9
106
EVs/mL.
This
immunoassay
exhibits
1.92
nM
equilibrium
dissociation
constant
bound
EVs,
suggesting
high
affinity
when
targeted.
study
provides
important
insights
into
development
targeted
antibodies,
which
has
applications
disease
diagnostics.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: Feb. 11, 2025
Epithelial
ovarian
cancer
(EOC),
one
of
the
most
prevalent
subtypes
cancer,
has
a
5-year
survival
rate
less
than
30%,
highlighting
urgent
need
for
novel
diagnostic
and
therapeutic
strategies.
The
tumor
microenvironment
(TME),
critical
regulator
progression,
includes
various
components,
among
which
small
extracellular
vesicles
(sEVs)
serve
as
important
molecular
carriers,
having
gained
attention
significant
contributors
to
biology.
These
vesicles,
released
by
cells
into
space,
are
pivotal
in
pathogenesis
EOC.
In
addition,
sEVs
show
promise
biomarkers
agents
treatment
management
this
malignancy.
This
review
explores
recent
advancements
understanding
within
TME
their
potential
applications
diagnosis
International Immunopharmacology,
Journal Year:
2025,
Volume and Issue:
150, P. 114303 - 114303
Published: Feb. 16, 2025
Ovarian
cancer
(OV)
remains
the
deadliest
gynecological
malignancy,
with
non-coding
RNA-mediated
transcriptomic
deregulation
significantly
influencing
its
prognosis
and
heterogeneous
progression.
In
this
study,
we
prioritized
miRNA-mediated
gene
expression
profiles
by
identifying
key
negative
correlations
between
miRNA-mRNA
pairs.
We
developed
a
machine
learning-based
index
(NCI),
incorporating
four-gene
signature
(GAS1,
GFPT2,
ZFHX4,
KCNA1)
to
predict
patient
therapeutic
response.
Validation
across
multiple
datasets
revealed
that
OV
patients
higher
NCI
scores
had
poorer
survival
outcomes
resistance
immunotherapy.
Additionally,
established
four-class
subtyping
taxonomy
through
unsupervised
clustering,
validated
in
four
independent
datasets.
The
S1
S3
subtypes
were
characterized
high
scores,
abundant
stromal
immune
infiltration,
subtype
exhibiting
worst
survival.
Conversely,
S2
showed
downregulation
of
response
genes,
while
S4
displayed
epithelial
differentiation
favourable
prognosis.
Integrative
analyses
bulk
single-cell
data
fibroblast
proportion
compared
other
subtypes,
whereas
was
marked
T
cell
content.
Through
ridge
regression-based
drug
sensitivity
analyses,
candidate
therapeutics
for
each
subtype.
Notably,
demonstrated
dasatinib
but
methotrexate.
Finally,
user-friendly
Shiny-based
website
facilitate
application
our
prognostic
classification
models
(https://jli-bioinfo.shinyapps.io/NCI_online/).
This
study
establishes
critical
marker
proposes
novel
molecular
framework
grounded
miRNA-regulated
profiles,
advancing
understanding
mechanisms
driving
heterogeneity.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 31, 2025
Checkpoint
blockade
combined
with
chemotherapy
has
become
an
important
treatment
option
for
lung
cancer
patients
in
clinical
settings.
However,
biomarkers
that
effectively
identify
true
responders
remain
lacking.
We
assessed
the
potential
of
plasma
small
extracellular
vesicle
(sEV)-derived
microRNAs
(miRNAs)
as
predicting
and
identifying
to
immunochemotherapy.
A
total
29
adenocarcinoma
who
received
pembrolizumab
pemetrexed
carboplatin
were
enrolled.
The
efficacy
evaluation
revealed
24
obtained
durable
benefits
from
immunochemotherapy,
rest
experienced
disease
progression.
Using
unsupervised
hierarchical
clustering,
56
differentially
expressed
miRNAs
(DEMs)
identified
between
nonresponders.
Efficacy
prediction
models
incorporating
a
combination
sEV
established
showed
good
performance
(area
under
curve
(AUC)
>
0.9).
In
addition,
we
found
miR-96-5p
miR-6815-5p
notably
downregulated
nonresponder
group,
while
miR-99b-3p,
miR-100-5p,
miR-193a-5p,
miR-320d
upregulated.
These
findings
further
confirmed
by
imaging.
derived
promise
